Ayad A. Al-Hamashi, PhD is an Assistant Professor of Pharmaceutical Chemistry at University of Baghdad. He earned his Bachelor of Pharmacy in 2004 and Masters of Pharmaceutical Chemistry in 2010 from University of Baghdad, Iraq. Dr. Al-Hamashi received his Doctor of Philosophy in Medicinal Chemistry from the University of Toledo, OH, USA in 2018. He performed a short post-doctoral experience in the area of chemical biology at Purdue University, IN, USA in 2018. He loves interacting with students at Pharmaceutical Chemistry Department and sharing his enthusiasm for his research activities. Dr. Al-Hamashi is focusing on the development of new antiproliferative molecules that acting on epigenetic abnormalities. Dr. Al-Hamashi is an expert in structure-based design of novel therapeutic molecules that tackling epigenetic overexpression associated with growth abnormalities.
-B.Sc. in Pharmacy (2004), College of Pharmacy, University of Baghdad. -M.Sc. in Pharmaceutical Chemistry (2010), College of Pharmacy, University of Baghdad. -Ph.D. in Medicinal Chemistry (2018), College of Pharmacy, University of Toledo, Ohio, USA. -Postdoctoral Fellowship in Medicinal Chemistry (2018), College of Pharmacy, Purdue University, Indiana, USA.
-Editorial Manager at Iraqi Journal of Pharmaceutical Sciences, 2024-present. -Member of the Ministry Committee for The Experts of Medical Sciences, 220223-present. -Chair of Department of Pharmaceutical Chemistry, 2020-2024. -Head of Foreign Students Equalization Committee - Iraq, 2021-2023. -Examination Committee Vice Chair, 2020-2021.
-Travel Award from the American Chemical Society (ACS), 2016 -Scholarship for graduate studies at the University of Toledo, 2012. -Second prize for best poster at the Mid-Atlantic Graduate Student Symposium (MAGSS), University of Toledo, 2014.
- Member of American Chemical Society (ACS).
- Member of American Association of Pharmaceutical Sciences (AAPS).
- Member of Phi Kappa Phi.
- Member of Sigma Phi Sigma.
- Member of Syndicate of Iraqi Pharmacists.
Dr. Al-Hamashi is focusing on the development of new antiproliferative molecules that acting on epigenetic abnormalities. Dr. Al-Hamashi is an expert in structure-based design of novel therapeutic molecules that tackling epigenetic overexpression associated with growth abnormalities.
Pharmaceuutical Chemistry Medicinal Chemistry Molecular Modeling Organic Synthesis Drug Design Drug Discovery
- Advanced Pharmaceutcal Biotechnology
- Bioorganic Mechanism I
- Bioorganic Mechanism II
- Bioorganic Mechanism
- Mechanism of Drug Action
- Instrumentation
- Drug Design and Molecular Modeling
- Pharmaceutical Chemistry II
- Pharmaceutical Chemistry III
- Pharmaceutical Chemistry IV
- Advaanced Pharmaceutical Analysis
- Organic Chemistry II
- Analytical chemistry Lab
- Organic Chemistry Lab
- Pharmaceutical Chemistry Lab
- Med chem Lab 3880 I and II (University of Toledo)
Academic Advisor to;
- 2 Ph.D. Students.
- 10 M.Sc. Students.
- 16 B.Sc. Students.
(17)
(14)
(29)
(26)
(51)
(51)
(13)
(8)
Protein arginine methyltransferases (PRMTs) play important roles in transcription, splicing, DNA damage repair, RNA biology, and cellular metabolism. Thus, PRMTs have been attractive targets for various diseases. In this study, we reported the design and synthesis of a potent pan-inhibitor for PRMTs that tethers a thioadenosine and various substituted guanidino groups through a propyl linker. Compound II757 exhibits a half-maximal inhibition concentration (IC50) value of 5 to 555 nM for eight tested PRMTs, with the highest inhibition for PRMT4 (IC50 = 5 nM). The kinetic study demonstrated that II757 competitively binds at the SAM binding site of PRMT1. Notably, II757 is selective for PRMTs over a panel of other methyltransferases, w
... Show More
(15)
(14)
In the course of generating a library of open-chain epothilones, we discovered a new class of small molecule anticancer agents that has no effect on tubulin but instead kills selected cancer cell lines by harnessing reactive oxygen species in an iron-dependent manner.
(10)
(11)